RxDoctor Payments DataLook up a doctor →

Ziad Younes, MD

Gastroenterology · Germantown, TNNPI 1285619874

Payments from drug & device makers

$15,586,441in general payments, 2019–2025

Across 3,327 payments — averaging $4684.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$5.7M
  • AbbVie$2.4M
  • Gilead$1.2M
  • Eli Lilly$1.1M
  • Madrigal Pharmaceuticals$992K
  • Janssen Research & Development, LLC$615K
  • plus $3.7M from 49 others
$105,875in research payments, 2019–2025

Across 27 payments — averaging $3921.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$64K
  • Eli Lilly$42K

What the payments were for

  • Consulting fees$50,1305%
  • Speaking & faculty fees$872,68184%
  • Travel & lodging$88,1098%
  • Food & beverage$30,1323%
  • Education$1300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.145$5,670,135
AbbVie(2 entities)752$2,374,405
Gilead238$1,221,686
Eli Lilly53$1,050,900
Madrigal Pharmaceuticals125$991,531
Janssen Research & Development, LLC214$614,837
F. Hoffmann-la Roche AG48$594,714
E.r. Squibb & Sons, L.L.C.60$553,570
Intercept Pharmaceuticals, Inc.168$549,266
Takeda Pharmaceuticals U.S.A., Inc.581$417,145
Ipsen Bioscience Inc.102$311,315
AstraZeneca5$244,687
Johnson & Johnson109$208,933
Lilly USA, LLC122$155,668
Novo Nordisk AS184$135,456
Janssen Scientific Affairs, LLC57$89,454
Pfizer61$69,955
Roche Products Limited33$66,466
Ironwood Pharmaceuticals, Inc11$65,856
Shire North American Group Inc12$54,065
Intercept Pharma Europe Ltd.5$42,819
Novartis3$25,286
Sanofi13$19,954
Teva Pharmaceuticals USA, Inc.3$17,200
Ipsen Biopharmaceuticals, Inc9$9,528
Novo Nordisk6$8,515
Ferring Pharmaceuticals Inc.8$4,823
Roche Diagnostics Corporation2$3,892
Mirum Pharmaceuticals, Inc.9$3,428
Bristol Myers Squibb22$2,872
Genmark Diagnostics, Inc.1$2,650
Genentech USA, Inc.5$2,236
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC82$1,335
Merck21$354
QOL Medical, LLC16$251
Mindray DS USA, Inc.1$230
Nestle Healthcare Nutrition Inc.8$157
Eisai Inc.1$116
Ardelyx, Inc.5$91
Phathom Pharmaceuticals, Inc.5$87
Ipsen Pharma SAS1$75
Exact Sciences1$73
Aimmune Therapeutics, Inc.4$71
Echosens North America, Inc.1$70
Regeneron Healthcare Solutions, Inc.2$68
Amgen3$63
Medtronic2$36
Daiichi Sankyo Inc.1$25
Celltrion USA Inc.1$16
Olympus America Inc.1$15
UCB, Inc.1$14
Endo Pharmaceuticals Inc.1$14
Evoke Pharma, Inc.1$13
Sanofi-aventis U.S. LLC1$13
Dynavax Technologies Corporation1$9

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,586,441 in reported general payments places this provider in the 95th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$182,942
Medicare patients
489
Services billed
4,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab32$876,174
Skyrizi On-BodyRisankizumab-Rzaa13$267,517
Humira(Cf) PenAdalimumab20$136,092
EntyvioVedolizumab15$125,319
CreonLipase/Protease/Amylase27$73,930
XifaxanRifaximin20$53,955
LinzessLinaclotide40$47,343
IbsrelaTenapanor Hcl14$24,548
Mesalamine37$17,622
Dexlansoprazole DrDexlansoprazole47$12,984
VoqueznaVonoprazan Fumarate19$12,828
ClenpiqSod Picosulf/Mag Ox/Citric Ac72$12,220
TrulancePlecanatide12$9,563
Budesonide DrBudesonide29$3,115
Ursodiol14$2,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$208,933$876,17432 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$417,145$125,31915 claims
AbbVieCreon, Linzess$2,374,405$121,27267 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$1,335$65,56647 claims
Ardelyx, Inc.Ibsrela$91$24,54814 claims
Phathom Pharmaceuticals, Inc.Voquezna$87$12,82819 claims
Ferring Pharmaceuticals Inc.Clenpiq$4,823$12,22072 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →